21 unknown, 19 recruiting, 15 completed, 12 active not recruiting. 67 Phase 2, 19 Phase 1, 9 Phase 3, 1 Early Phase 1.
Follow AK104: new trials by email Literature Review of AK104 trials Research Report on AK104
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase II Clinical Study of AK104/AK112 in Combination With TT-00420 Tablet for Advanced HCC. TT-00420 (tinengotinib), AK104, AK112 - Hepatocellular Carcinoma (HCC) | Phase 2 | Recruiting | Akeso | 100 | 2025-07-18 | 2026-03-16 |
| Comparison of Neoadjuvant Cadonilimab Versus Chemotherapy Combined With PD-1 in the Treatment of Resectable Non-Small Cell Lung Cancer With High PD-L1 Expression: A Single-Center, Randomized, Exploratory Clinical Study AK104 - Resectable Non-small Cell Lung Cancer, Bispecific Antibody | Phase 2 | Not yet recruiting | Shanghai Pulmonary Hospital, Shanghai, China | 80 | 2025-04-21 | 2025-04-27 |
| IN10018 With Nab-Paclitaxel and Cadonilimab for Metastatic or Recurrent Gastric-Type Cervical Adenocarcinoma: Phase 2 Trial IN10018, Nab-paclitaxel, Cadonilimab - Cervical Adenocarcinoma, Gastric-type Endocervical Adenocarcinoma | Phase 2 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 25 | 2025-02-17 | 2026-01-13 |
| An Exploratory, Multi-cohort Phase II Study of Combination Therapy With AK104 and AK112 for Recurrent Ovarian Cancer AK104, AK112, Chemotherapy - Recurrent Ovarian Cancer | Phase 2 | Recruiting | Akeso | 172 | 2024-11-12 | 2025-03-12 |
| A Trial of Cadonilimab With Adriamycin in Patients With Advanced Soft Tissue Sarcoma Cadonilimab, Adriamycin - Advanced Soft-tissue Sarcoma | Phase 2 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 53 | 2024-10-09 | 2025-07-18 |
| Efficacy and Safety of AK104 (PD-1/CTLA-4 Bispecial Antibody) Combined With Chemotherapy for Neoadjuvant Treatment of Advanced Ovarian Cancer AK104 - Advanced Ovarian Cancer, AK104(PD-1/CTLA-4 Bispecial Antibody) | Phase 3 | Not yet recruiting | Anhui Provincial Hospital | 100 | 2024-10-01 | 2024-08-07 |
| Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer Cadonilimab, Paclitaxel-albumin, Cisplatin - Cervical Cancer, Neoadjuvant Chemoimmunotherapy | Phase 2 | Recruiting | Tongji Hospital | 50 | 2024-09-03 | 2024-09-19 |
| Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC Patients Vorolanib, cadonilimab - Kidney Cancer, RCC | Phase 1 / Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 37 | 2024-08-31 | 2024-08-29 |
| A Study of AK104+Lenvatinib in Combination With Transarterial Chemoembolization (TACE) Versus TACE in Participants With Incurable/Non-metastatic Hepatocellular Carcinoma AK104, Lenvatinib, TACE - Hepatocellular Carcinoma | Phase 3 | Recruiting | Akeso | 469 | 2024-08-02 | 2025-03-12 |
| Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients cadonilimab, Trastuzumab, XELOX - Metastatic HER2 Positive Gastroesophageal Junction Cancer | Phase 1 / Phase 2 | Recruiting | Zhejiang Cancer Hospital | 90 | 2024-07-10 | 2024-10-21 |
| RC48 Plus AK104 as First-line Treatment for HER2-overexpressing Advanced Gastric Cancer Disitamab Vedotin, Cadonilimab - HER2-positive Gastric Cancer | Phase 2 | Not yet recruiting | The First Affiliated Hospital of Zhengzhou University | 20 | 2024-07-06 | 2024-07-09 |
| AG Combined With Cadonilimab Sequential Short-course Radiotherapy in the Treatment of Locally aPDAC Cadonilimab, Gemcitabine, Nab-Paclitaxel - Locally Advanced Pancreatic Ductal Adenocarcinoma | Phase 2 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 30 | 2024-07-01 | 2024-12-04 |
| Study of Cadonilimab Combined With Chemotherapy in Recurrent / Refractory Pleural Mesothelioma Cadonilimab Combined with chemotherapy - Pleural Mesothelioma | Phase 2 | Not yet recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 59 | 2024-06-20 | 2024-05-16 |
| A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma cadonilimab, pulocimab, paclitaxel - Gastric and Gastroesophageal Junction Adenocarcinoma | Phase 3 | Recruiting | Akeso | 506 | 2024-06-19 | 2024-06-24 |
| Cadonilimab With Chemoradiation for Recurrent and Oligometastatic Endometrial Carcinoma Paclitaxel and Cisplatin, Cadonilimab, Radiotherapy - Endometrial Neoplasms, Neoplasm Recurrence, Local | Phase 2 | Recruiting | Shandong Cancer Hospital and Institute | 30 | 2024-06-13 | 2026-04-24 |
| Cadonilimab in Combination With Ramucirumab for the Treatment of Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy Cadonilimab Injection, Ramucirumab Injection - Advanced Hepatocellular Carcinoma That Has Failed at Systemic Therapy | Phase 1 | Unknown | Tianjin Medical University Cancer Institute and Hospital | 30 | 2024-06-01 | 2024-04-15 |
| Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC AK104, Etoposide, Carboplatin - SCLC, Extensive Stage | Phase 1 / Phase 2 | Active not recruiting | Sichuan University | 57 | 2024-05-16 | 2026-04-29 |
| Cadonilimab in Combination With Anlotinib in the Treatment of Locally Progressive or Metastatic Melanoma With First-Line Therapy Failure Cadonilimab, anlotinib - Melanoma | Phase 2 | Not yet recruiting | Hunan Cancer Hospital | 30 | 2024-05-15 | 2024-03-25 |
| Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular Carcinoma Cadonilimab, Lenvatinib - Hepatocellular Carcinoma | Phase 2 | Recruiting | Hunan Cancer Hospital | 30 | 2024-05-15 | 2024-05-09 |
| AK104 in Combination With AK112 Plus Chemotherapy(SOX/XELOX) as First-line Treatment for Advanced G/GEJ Cancer Cadonilimab, Ivonescimab, XELOX - Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | Phase 2 | Recruiting | Harbin Medical University | 50 | 2024-04-10 | 2024-06-27 |
Showing 20 of 82. Sign in to see all of them.
Uterine Cervical Neoplasms (10) · Carcinoma, Hepatocellular (7) · Carcinoma, Non-Small-Cell Lung (4) · Nasopharyngeal Carcinoma (4) · Carcinoma, Renal Cell (3) · Endometrial Neoplasms (3) · Esophageal Squamous Cell Carcinoma (3) · Diabetes Mellitus, Insulin-Dependent, 12 (2) · Melanoma (2) · Mesothelioma, Malignant (2) · Neoplasms (2) · Stomach Neoplasms (2) · Carcinoma (1) · Carcinoma, Transitional Cell (1) · Colorectal Neoplasms (1)
Akeso (29) · Sun Yat-sen University (6) · Tianjin Medical University Cancer Institute and Hospital (5) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (3) · Union Hospital, Tongji Medical College, Huazhong University of Science and Technology (3) · Fujian Cancer Hospital (2) · Hunan Cancer Hospital (2) · Akesobio Australia Pty Ltd (1) · Anhui Provincial Hospital (1) · Chinese Academy of Medical Sciences (1) · First Affiliated Hospital of Guangxi Medical University (1) · Guangxi Medical University (1) · Guangzhou Institute of Respiratory Disease (1) · Hao Zeng (1) · Harbin Medical University (1)
China (66) · Australia (3) · United States (2) · New Zealand (1)
Lin Shen, MD (3) · Guoliang Shao, MD (2) · Ruihua Xu, MD (2) · Amir Jazaeri (1) · Baohui Han, M.D (1) · Chong Zhao, MD, PhD (1) · Ding Ma (1) · Dingwei Ye, MD (1) · Gaojun Teng, MD (1) · Guoxin Li, M.D., Ph.D (1) · Han Liang, MD (1) · Hanmei Lou (1) · Hao Zeng, Professor (1) · Hu Ma, Ph.D (1) · Hui Qiu, Ph.D. (1)
PMID 35108470, PMID 36569905, PMID 36990609, PMID 37677918, PMID 37797632, PMID 37852261, PMID 37942328, PMID 38372727, PMID 38706247, PMID 39426385, PMID 39843940, PMID 40389320, PMID 40705040, PMID 41167638, PMID 41293180, PMID 41582028, PMID 42000370, PMID 42682622, PMID 42838953